NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Lumora today announced a licensing deal to develop tests for veterinary diagnostics company Biogal Galed Labs.

The deal provides Israel-based Biogal access to Lumora's technologies, including BART, or Bioluminescent Assay in Real Time, as well as its expertise in test development, reader technologies, and manufacturing, Lumora said. Initially, Lumora will develop a test for leptospirosis, a zoonotic bacterial infection that is transmitted through urine.

Development of other tests is expected to follow.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.